Aquinox Pharmaceuticals (NASDAQ:AQXP) issued its quarterly earnings results on Monday, March 12th. The company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.59) by ($0.10), Yahoo Finance reports.
Shares of NASDAQ:AQXP traded up $0.06 during trading on Thursday, reaching $13.91. The stock had a trading volume of 24,410 shares, compared to its average volume of 112,474. The firm has a market capitalization of $321.12, a PE ratio of -6.50 and a beta of -14.30. Aquinox Pharmaceuticals has a 1-year low of $10.02 and a 1-year high of $16.90.
Several brokerages recently weighed in on AQXP. ValuEngine upgraded Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Monday. BidaskClub upgraded Aquinox Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Monday, February 5th. Zacks Investment Research cut Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, March 16th. Canaccord Genuity set a $22.00 price objective on Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, December 19th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $28.00 price objective on shares of Aquinox Pharmaceuticals in a research report on Sunday, February 11th. One analyst has rated the stock with a sell rating, two have issued a hold rating and four have assigned a buy rating to the company. The company has an average rating of “Hold” and an average price target of $22.80.
COPYRIGHT VIOLATION WARNING: This piece of content was originally posted by BBNS and is the property of of BBNS. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US & international copyright & trademark law. The legal version of this piece of content can be read at https://baseballnewssource.com/2018/04/05/aquinox-pharmaceuticals-aqxp-announces-earnings-results-misses-estimates-by-0-10-eps/2027616.html.
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.